Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Atea Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Atea Pharmaceuticals, Inc.’s stock price such as:

• Atea Pharmaceuticals, Inc.’s current stock price and volume
• Why Atea Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for AVIR from analysts
• AVIR’s stock price momentum as measured by its relative strength

About Atea Pharmaceuticals, Inc. (AVIR)

Before we jump into Atea Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Want to learn more about Atea Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Atea Pharmaceuticals, Inc.’s stock price was $4.700.

Atea Pharmaceuticals, Inc. is down 0.84% from its previous closing price of $4.740.

During the last market session, Atea Pharmaceuticals, Inc.’s stock traded between $4.690 and $4.980. Currently, there are approximately 79.20 million shares outstanding for Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Atea Pharmaceuticals, Inc. Stock Price History

Atea Pharmaceuticals, Inc.’s (AVIR) price is currently up 1.08% so far this month.

During the month of July, Atea Pharmaceuticals, Inc.’s stock price has reached a high of $5.040 and a low of $3.820.

Over the last year, Atea Pharmaceuticals, Inc. has hit prices as high as $6.450 and as low as $2.780. Year to date, Atea Pharmaceuticals, Inc.’s stock is up 31.65%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Atea Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Atea Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Atea Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Atea Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Atea Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Atea Pharmaceuticals, Inc. (AVIR) by visiting AAII Stock Evaluator.

Relative Price Strength of Atea Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Atea Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 0.83%, which translates to a Momentum Score of 55 and is considered to be Average.

Want to learn more about how Atea Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Atea Pharmaceuticals, Inc. Stock Price: Bottom Line

As of July 31, 2026, Atea Pharmaceuticals, Inc.’s stock price is $4.700, which is down 0.84% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Atea Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.